Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc has a market capitalization of $191.31 million and a price-to-earnings ratio of 124.55, indicating a high valuation relative to its earnings. The company's liquidity position is characterized by a current ratio of 5.28, suggesting strong short-term liquidity, but its operating cash flow is negative at -$1.48 million, indicating cash outflows from operations. The company's free cash flow is positive at $1.59 million, which is a positive sign for its ability to fund operations and growth.

In terms of profitability, Oramed's return on equity is 0.92%, and its return on assets is 0.75%, both of which are below the industry median for biotechnology and medical research firms. The company's net income is $1.54 million, but its operating income is negative at -$2.96 million, indicating that operational costs exceed revenues. The debt-to-equity ratio is 0.19, suggesting a relatively low level of financial leverage.

Oramed's revenue is not disclosed in the latest financial data, but the company's total assets are $203.65 million, and its total liabilities are $37.01 million. The company's long-term debt is $32.03 million, and its cash and equivalents are $18.58 million. The company's capital expenditure is minimal at -$2,000, indicating little investment in physical assets.

The company's growth trajectory is uncertain, as its revenue is not disclosed in the latest financial data. However, the company's net income is positive at $1.54 million, which is a positive sign for its financial health. The company's operating income is negative, which may indicate challenges in managing operational costs.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag is that net cash is negative after subtracting total debt, which may affect the company's ability to meet its short-term obligations. The company's debt-to-equity ratio is 0.19, which is relatively low, but the negative operating cash flow may indicate potential liquidity issues.

Recent events include a positive net income of $1.54 million and a negative operating income of -$2.96 million. The company's ESG scores are 9.91 for the social pillar and 43.57 for the governance pillar, indicating a moderate level of social responsibility and governance. The company's last actual revenue is reported at $2.00 million, and the last actual EPS is $1.50.

Analysts project 55.1% upside to a $6.25 price target, signaling strong market confidence in the company's future potential.

The company maintains a low leverage band with a robust current ratio of 6.98, indicating strong short-term liquidity.

Return on equity of 0.92% significantly outperforms the biotechnology cohort median of -21.82%, demonstrating superior capital efficiency.

Projected 2026 net income of $64.05 million represents a substantial turnaround from the $19.06 million loss in 2025.

Revenue is forecast to grow at a 22.0% CAGR over four years, reaching $2.0 million by fiscal year 2026.

The company faces high credit risk, suggesting significant concerns regarding its ability to meet long-term financial obligations.

Return on invested capital remains negative at -1.49%, indicating the company fails to generate adequate returns on its capital base.

Cash conversion metrics rank in the bottom quartile of the biotechnology cohort, highlighting poor operational cash generation efficiency.

Operating income remains deeply negative at -$15.09 million in 2026, showing persistent inability to achieve operational profitability.

Medium liquidity risk flags suggest potential challenges in meeting immediate financial demands despite strong current ratios.

Revenue $0.00; Operating income −57,8% YoY.

• ▍Revenue $0.00
• ▍Operating income −57,8% YoY
• ▍Net income +198,2% YoY
• ▍Free cash flow +198,6% YoY

Revenue $0.00; Operating income +21,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +21,4% YoY
• ▍Net income +346,7% YoY
• ▍Free cash flow +347,1% YoY

Revenue $0.00; Operating income +20,6% YoY.

• ▍Revenue $0.00
• ▍Operating income +20,6% YoY
• ▍Net income +44,2% YoY
• ▍Free cash flow +43,5% YoY

Revenue $2.0M; Operating income −51,9% YoY.

• ▍Revenue $2.0M
• ▍Operating income −51,9% YoY
• ▍Net income −597,5% YoY
• ▍Free cash flow −579,5% YoY
• ▍Net margin -382.1%

Revenue $0.00; Operating income -$3.6M.

• ▍Revenue $0.00
• ▍Operating income -$3.6M

Revenue $0.00; Operating income -$3.1M.

• ▍Revenue $0.00
• ▍Operating income -$3.1M

Revenue $0.00; Operating income -$3.1M.

• ▍Revenue $0.00
• ▍Operating income -$3.1M

Revenue $0.00; Operating income -$3.0M.

• ▍Revenue $0.00
• ▍Operating income -$3.0M

Revenue $2.0M; Operating income −18,1% YoY.

• ▍Revenue $2.0M
• ▍Operating income −18,1% YoY
• ▍Net income +436,0% YoY
• ▍Free cash flow +438,8% YoY
• ▍Net margin 3202.5%

Revenue $0.00, −100,0% YoY; Operating income +18,9% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +18,9% YoY
• ▍Net income −445,0% YoY
• ▍Free cash flow −476,3% YoY

Revenue $1.3M, −50,4% YoY; Operating income +61,2% YoY.

• ▍Revenue $1.3M, −50,4% YoY
• ▍Operating income +61,2% YoY
• ▍Net income +115,1% YoY
• ▍Free cash flow +113,2% YoY
• ▍Net margin 412.3%

Revenue $2.7M, +199,0% YoY; Operating income −229,4% YoY.

• ▍Revenue $2.7M, +199,0% YoY
• ▍Operating income −229,4% YoY
• ▍Net income −213,3% YoY
• ▍Net margin -1352.6%